Search Within

Shanu Modi

  1. "2024"
Formats
  1. Journal Article (13)
  2. Meeting Abstract (8)
  3. Review (2)
Groups
  1. Breast Medicine Service (23)
  2. Department of Medicine (23)
  3. Solid Tumor Oncology Division (23)
  4. GSK Faculty (8)
  5. Survivorship Research (7)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (6)

More Groups

People
  1. Mark Robson (6)
  2. Sarat Chandarlapaty (5)
  3. Chau Dang (4)
  4. Emanuela Ferraro (4)
  5. Pedram Razavi (4)
  6. Anton Safonov (3)

More People

Years
  1. 2024 (23)
Publications
  1. Journal of Clinical Oncology (6)
  2. Annals of Oncology (4)
  3. Nature Communications (2)
  4. npj Breast Cancer (2)
  5. Breast Cancer (1)
  6. Breast Cancer Research and Treatment (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (6)
  2. Nature Publishing Group (5)
  3. Oxford University Press (5)
  4. Springer (2)
  5. Elsevier Science, Inc. (1)
  6. European Society for Medical Oncology (1)

More Publishers

Results (23)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04
    Meeting Abstract

    Ueno, N. T.; Niikura, N.; Yamashita, T.; Jacot, W.; Cameron, D. A.; Tsurutani, J.; Sohn, J.; Tokunaga, E.; Losada, M. J. V.; Park, Y. H.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
    Meeting Abstract

    Modi, S.; Byng, D.; Zhang, S.; Xiong, Y.; Hunter, S.; Struebing, A.; Dunton, K.; Mbanya, Z.; Jacot, W.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
    Journal Article

    André, F.; Cortés, J.; Curigliano, G.; Modi, S.; Li, W.; Park, Y. H.; Chung, W. P.; Kim, S. B.; Yamashita, T.; Pedrini, J. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Journal Article

    Chew, S. M.; Ferraro, E.; Chen, Y.; Barrio, A. V.; Kelly, D.; Modi, S.; Seidman, A. D.; Wen, H.; Brogi, E.; Robson, M.; more...
    npj Breast Cancer (2024)

    Fulltext@MSK | Save
  • Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Journal Article

    Mai, N.; dos Anjos, C. H.; Razavi, P.; Safonov, A.; Patil, S.; Chen, Y.; Drago, J. Z.; Modi, S.; Bromberg, J. F.; Dang, C. T.; more...
    npj Breast Cancer (2024)

    Fulltext@MSK | Save
  • Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferation
    Journal Article

    Roychowdhury, T.; McNutt, S. W.; Pasala, C.; Nguyen, H. T.; Thornton, D. T.; Sharma, S.; Botticelli, L.; Digwal, C. S.; Joshi, S.; Yang, N.; more...
    Nature Communications (2024)

    Fulltext@MSK | Save
  • Managed care considerations in the treatment of HER2-positive advanced breast cancer: A closer look at recent advances for improved patient outcomes
    Journal Article

    Modi, S.
    Journal of Managed Care Medicine (2024)

    Fulltext@MSK | Save
  • Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03
    Meeting Abstract

    Saura, C.; Cortés, J.; Modi, S.; Kim, S. B.; Hamilton, E. P.; Hurvitz, S. A.; Krop, I. E.; Curigliano, G.; Iwata, H.; Im, S. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies
    Meeting Abstract

    Park, Y. H.; Cortes, J.; Modi, S.; Hurvitz, S. A.; Bianchini, G.; Iwata, H.; Shitara, K.; Siena, S.; Goto, Y.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
    Meeting Abstract

    Sands, J.; Tolaney, S. M.; Ueno, N. T.; Spira, A. I.; Yamamoto, N.; Janjigian, Y. Y.; Naito, Y.; Damodaran, S.; Meric-Bernstam, F.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save